Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the effectiveness of statins in the treatment of moyamoya disease based on multimodal magnetic resonance imaging.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Revascularization/Conservative management | Drug | Revascularization/Conservative management |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of participants experiencing cerebrovascular events (TIA, ischemic stroke, or hemorrhagic stroke) | The occurrence of cerebrovascular events, including TIA, ischemic stroke, or hemorrhagic stroke, will be assessed over an 18-month follow-up period. | 18 months during follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Neurological Function (mRS, NIHSS) at 12 and 18 Months After Treatment | The mRS and NIHSS will be used to assess changes in neurological function at 12 and 18 months after treatment. | 12 and 18 months during follow-up |
| Changes in Cognitive Function (MoCA, MMSE) at 12 and 18 Months After Treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients diagnosed with MMD in Beijing Tiantan Hospital will be recruited. Eligibility will be determined through a checklist of inclusion and exclusion criteria.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Qian Zhang | Contact | 8613120012579 | zhangqianchina@yahoo.com | |
| Chaofan Zeng | Contact | 8613693276138 | zchf723@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing Tiantan Hospital | Recruiting | Beijing | China | 100070 | China |
Not provided
| ID | Term |
|---|---|
| D009072 | Moyamoya Disease |
| ID | Term |
|---|---|
| D002340 | Carotid Artery Diseases |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000072700 | Conservative Treatment |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood
The MoCA and MMSE will be used to evaluate changes in cognitive function at 12 and 18 months after treatment. |
| 12 and 18 months during follow-up |
| Structural Remodeling of the Internal Carotid Artery Terminal and Middle Cerebral Artery Wall at 12 and 18 Months After Treatment | High-resolution magnetic resonance vessel wall imaging will be used to evaluate structural remodeling changes in the internal carotid artery terminal and middle cerebral artery wall at 12 and 18 months after treatment. | 12 and 18 months during follow-up |
| Changes in Cerebral Blood Perfusion at 12 and 18 Months After Treatment | ASL will be used to assess cerebral blood perfusion changes at 12 and 18 months after treatment. | 12 and 18 months during follow-up |
| Rate of New Cerebral Infarcts at 12 and 18 Months After Treatment | The occurrence of new cerebral infarcts at 12 and 18 Months after treatment will be evaluated using MRI. | 12 and 18 months during follow-up |
| Hemodynamic Changes at the Internal Carotid Artery Terminal at 12 and 18 Months After Treatment | 4D-Flow MRI and hemodynamic analysis will be used to evaluate changes in hemodynamics at the internal carotid artery terminal at 12 and 18 months after treatment. | 12 and 18 months during follow-up |
| Changes in Blood Lipid Levels at 12 and 18 Months After Treatment | Blood lipid levels will be measured and compared at 12 and 18 months after treatment. | 12 and 18 months during follow-up |
| D009422 | Nervous System Diseases |
| D002539 | Cerebral Arterial Diseases |
| D020765 | Intracranial Arterial Diseases |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |